Edwards Lifesciences Corp Stock Working Capital
EW Stock | USD 95.56 0.41 0.43% |
Edwards Lifesciences Corp fundamentals help investors to digest information that contributes to Edwards Lifesciences' financial success or failures. It also enables traders to predict the movement of Edwards Stock. The fundamental analysis module provides a way to measure Edwards Lifesciences' intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Edwards Lifesciences stock.
Net Working Capital is likely to drop to about 2.2 B in 2024. Change In Working Capital is likely to climb to about (500 M) in 2024. Edwards | Working Capital |
Edwards Working Capital Analysis
Edwards Lifesciences' Working Capital is a measure of company efficiency and operating liquidity. The working capital is usually calculated by subtracting Current Liabilities from Current Assets. It is an important indicator of the firm ability to continue its normal operations without additional debt obligations. .
More About Working Capital | All Equity Analysis
2021 | 2022 | 2023 | 2024 (projected) | Other Current Liabilities | 3.9M | 311M | 15.2M | 14.4M | Total Assets | 8.5B | 8.3B | 9.4B | 9.8B |
Working Capital | = | Current Assets | - | Current Liabilities |
Current Edwards Lifesciences Working Capital | 2.84 B |
Most of Edwards Lifesciences' fundamental indicators, such as Working Capital, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Edwards Lifesciences Corp is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Edwards Working Capital Driver Correlations
Understanding the fundamental principles of building solid financial models for Edwards Lifesciences is extremely important. It helps to project a fair market value of Edwards Stock properly, considering its historical fundamentals such as Working Capital. Since Edwards Lifesciences' main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of Edwards Lifesciences' historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of Edwards Lifesciences' interrelated accounts and indicators.
Click cells to compare fundamentals
Working Capital can be positive or negative, depending on how much of current debt the company is carrying on its balance sheet. In general terms, companies that have a lot of working capital will experience more growth in the near future since they can expand and improve their operations using existing resources. On the other hand, companies with small or negative working capital may lack the funds necessary for growth or future operation. Working Capital also shows if the company has sufficient liquid resources to satisfy short-term liabilities and operational expenses.
Competition |
Edwards Capital Surpluse
Capital Surpluse |
|
According to the company's disclosures, Edwards Lifesciences Corp has a Working Capital of 2.84 B. This is much higher than that of the Health Care Equipment & Supplies sector and 108.7% higher than that of the Health Care industry. The working capital for all United States stocks is 92.15% lower than that of the firm.
Edwards Working Capital Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Edwards Lifesciences' direct or indirect competition against its Working Capital to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Edwards Lifesciences could also be used in its relative valuation, which is a method of valuing Edwards Lifesciences by comparing valuation metrics of similar companies.Edwards Lifesciences is rated # 2 in working capital category among related companies.
Edwards Lifesciences ESG Sustainability
Some studies have found that companies with high sustainability scores are getting higher valuations than competitors with lower social-engagement activities. While most ESG disclosures are voluntary and do not directly affect the long term financial condition, Edwards Lifesciences' sustainability indicators can be used to identify proper investment strategies using environmental, social, and governance scores that are crucial to Edwards Lifesciences' managers, analysts, and investors.Environment Score | Governance Score | Social Score |
Edwards Fundamentals
Return On Equity | 0.22 | ||||
Return On Asset | 0.12 | ||||
Profit Margin | 0.23 % | ||||
Operating Margin | 0.39 % | ||||
Current Valuation | 56.57 B | ||||
Shares Outstanding | 601.3 M | ||||
Shares Owned By Insiders | 0.88 % | ||||
Shares Owned By Institutions | 83.60 % | ||||
Number Of Shares Shorted | 10.45 M | ||||
Price To Earning | 32.77 X | ||||
Price To Book | 8.65 X | ||||
Price To Sales | 9.57 X | ||||
Revenue | 6 B | ||||
Gross Profit | 4.3 B | ||||
EBITDA | 1.53 B | ||||
Net Income | 1.4 B | ||||
Cash And Equivalents | 769 M | ||||
Cash Per Share | 2.81 X | ||||
Total Debt | 694.9 M | ||||
Debt To Equity | 0.11 % | ||||
Current Ratio | 3.83 X | ||||
Book Value Per Share | 11.06 X | ||||
Cash Flow From Operations | 895.8 M | ||||
Short Ratio | 2.57 X | ||||
Earnings Per Share | 2.31 X | ||||
Price To Earnings To Growth | 5.49 X | ||||
Target Price | 92.36 | ||||
Number Of Employees | 19.8 K | ||||
Beta | 1.05 | ||||
Market Capitalization | 57.46 B | ||||
Total Asset | 9.36 B | ||||
Retained Earnings | 8.99 B | ||||
Working Capital | 2.84 B | ||||
Current Asset | 2.05 B | ||||
Current Liabilities | 476.2 M | ||||
Z Score | 52.5 | ||||
Net Asset | 9.36 B |
About Edwards Lifesciences Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Edwards Lifesciences Corp's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Edwards Lifesciences using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Edwards Lifesciences Corp based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.Last Reported | Projected for 2024 | ||
Net Working Capital | 2.8 B | 2.2 B | |
Change In Working Capital | -526.3 M | -500 M |
Pair Trading with Edwards Lifesciences
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Edwards Lifesciences position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Edwards Lifesciences will appreciate offsetting losses from the drop in the long position's value.Moving together with Edwards Stock
0.89 | BSX | Boston Scientific Corp Financial Report 24th of April 2024 | PairCorr |
0.68 | COO | Cooper Companies Financial Report 6th of June 2024 | PairCorr |
Moving against Edwards Stock
0.86 | MCRB | Seres Therapeutics Financial Report 14th of May 2024 | PairCorr |
0.81 | PHG | Koninklijke Philips Financial Report 22nd of April 2024 | PairCorr |
0.73 | MBIO | Mustang Bio Report 3rd of April 2024 | PairCorr |
0.71 | PIIIW | P3 Health Partners | PairCorr |
0.69 | TFX | Teleflex Incorporated Financial Report 2nd of May 2024 | PairCorr |
The ability to find closely correlated positions to Edwards Lifesciences could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Edwards Lifesciences when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Edwards Lifesciences - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Edwards Lifesciences Corp to buy it.
The correlation of Edwards Lifesciences is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Edwards Lifesciences moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Edwards Lifesciences Corp moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Edwards Lifesciences can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Check out Edwards Lifesciences Piotroski F Score and Edwards Lifesciences Altman Z Score analysis. You can also try the Piotroski F Score module to get Piotroski F Score based on the binary analysis strategy of nine different fundamentals.
Complementary Tools for Edwards Stock analysis
When running Edwards Lifesciences' price analysis, check to measure Edwards Lifesciences' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Edwards Lifesciences is operating at the current time. Most of Edwards Lifesciences' value examination focuses on studying past and present price action to predict the probability of Edwards Lifesciences' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Edwards Lifesciences' price. Additionally, you may evaluate how the addition of Edwards Lifesciences to your portfolios can decrease your overall portfolio volatility.
Balance Of Power Check stock momentum by analyzing Balance Of Power indicator and other technical ratios | |
Investing Opportunities Build portfolios using our predefined set of ideas and optimize them against your investing preferences | |
Premium Stories Follow Macroaxis premium stories from verified contributors across different equity types, categories and coverage scope | |
Odds Of Bankruptcy Get analysis of equity chance of financial distress in the next 2 years | |
Sectors List of equity sectors categorizing publicly traded companies based on their primary business activities |
Is Edwards Lifesciences' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Edwards Lifesciences. If investors know Edwards will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Edwards Lifesciences listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth (0.06) | Earnings Share 2.31 | Revenue Per Share 9.897 | Quarterly Revenue Growth 0.138 | Return On Assets 0.1225 |
The market value of Edwards Lifesciences Corp is measured differently than its book value, which is the value of Edwards that is recorded on the company's balance sheet. Investors also form their own opinion of Edwards Lifesciences' value that differs from its market value or its book value, called intrinsic value, which is Edwards Lifesciences' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Edwards Lifesciences' market value can be influenced by many factors that don't directly affect Edwards Lifesciences' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Edwards Lifesciences' value and its price as these two are different measures arrived at by different means. Investors typically determine if Edwards Lifesciences is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Edwards Lifesciences' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.